{
    "organizations": [],
    "uuid": "76254954879884d15ee1018d5f08ecc3aaf58af2",
    "author": "",
    "url": "https://www.reuters.com/article/brief-cardurion-pharmaceuticals-licenses/brief-cardurion-pharmaceuticals-licenses-clinical-stage-heart-failure-candidate-from-astellas-idUSFWN1RT0N4",
    "ord_in_thread": 0,
    "title": "BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 16, 2018 / 1:06 PM / Updated 10 minutes ago BRIEF-Cardurion Pharmaceuticals Licenses Clinical Stage Heart Failure Candidate From Astellas Reuters Staff \nApril 16 (Reuters) - Astellas Pharma Inc: \n* CARDURION PHARMACEUTICALS LICENSES CLINICAL STAGE HEART FAILURE CANDIDATE FROM ASTELLAS \n* CARDURION PHARMACEUTICALS - ENTERED EXCLUSIVE LICENSING AGREEMENT WITH ASTELLAS TO DEVELOP AND COMMERCIALIZE CRD-733 Source text for Eikon: Further company coverage:",
    "published": "2018-04-16T16:03:00.000+03:00",
    "crawled": "2018-04-16T16:23:15.003+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "pm",
        "updated",
        "minute",
        "ago",
        "pharmaceutical",
        "license",
        "clinical",
        "stage",
        "heart",
        "failure",
        "candidate",
        "astellas",
        "reuters",
        "staff",
        "april",
        "reuters",
        "astellas",
        "pharma",
        "inc",
        "cardurion",
        "pharmaceutical",
        "license",
        "clinical",
        "stage",
        "heart",
        "failure",
        "candidate",
        "astellas",
        "cardurion",
        "pharmaceutical",
        "entered",
        "exclusive",
        "licensing",
        "agreement",
        "astellas",
        "develop",
        "commercialize",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}